Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III adjuvant trial of SHR-A1811 versus trastuzumab emtansine in HER2-positive breast cancer with residual invasive disease after neoadjuvant therapy
CTR20233610Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan, trastuzumab emtansine in breast cancer, sponsored by Hengrui Therapeutics. Started Nov 2023; status: active.
02
Drugs
trastuzumab rezetecantrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20233610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233610.